Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9929 - 9936 of 12089 results

Apply by January 6 to Pitch Your Energy Start-Up at the ARPA-E Energy Innovation Summit
December 30, 2014| Blog| Viewpoint

Delaware Supreme Court Holds That Court of Chancery Can Restrict Forum Where Books and Records Can Be Used
December 30, 2014| Blog| Viewpoint

Off-Key BABs: IRS Hits Wrong Note in Reissuance Analysis
December 30, 2014| Blog| Viewpoint

The Affordable Care Act—Countdown to Compliance for Employers, Week 0: Final Thoughts and Acknowledgements
December 29, 2014| Blog| Viewpoint

SEC Proposes Changes to Exchange Act Rules to Implement Title V and Title VI of the JOBS Act
December 29, 2014| Blog| Viewpoint

FCC's Retroactive Solicited Fax Opt-Out Waiver Window Closing
December 29, 2014| Blog| Viewpoint

Consumer Claims Survive Motion to Dismiss in Target Data Breach Class Action
December 29, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
